HROW - Harrow Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.94
+0.11 (+1.85%)
As of 3:37PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.83
Open5.86
Bid5.87 x 800
Ask5.90 x 2900
Day's Range5.72 - 6.02
52 Week Range1.99 - 7.20
Volume113,103
Avg. Volume227,628
Market Cap146.688M
Beta (3Y Monthly)-1.56
PE Ratio (TTM)5.08
EPS (TTM)1.17
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.38
Trade prices are not sourced from all markets
  • PR Newswire18 days ago

    Novel Drug Solutions, LLC and Eye Care Northwest, PA Terminates Agreement with Harrow Health, Inc.

    ROSELAND, N.J., May 30, 2019 /PRNewswire/ -- Axiom Communications, on behalf of Novel Drug Solutions, LLC and Eye Care Northwest, PA announced today that the companies have delivered a Notice of Termination and Cease and Desist directive to Harrow Health, Inc. (NASDAQ: HROW formerly known as Imprimis Pharmaceuticals, Inc.).

  • GlobeNewswire19 days ago

    Harrow Health Announces Renegotiated Debt Facility with SWK Holdings

    Harrow Health, Inc. (HROW) today announced it has amended its loan agreement with SWK Funding LLC and its partners.  SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a healthcare-focused investment firm.

  • Associated Presslast month

    Harrow: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had profit of 43 cents. Losses, adjusted for non-recurring gains, came to 2 cents per share. The pharmaceutical and drug compounding company posted ...

  • GlobeNewswirelast month

    Harrow Health Announces First Quarter 2019 Financial Results

    The company’s management team will host a conference call and audio-only webcast today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and other recent developments.  To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until June 9, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 48440.  The webcast replay will be available until August 9, 2019.

  • GlobeNewswirelast month

    Harrow Health to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

    SAN DIEGO, May 07, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company’s business.

  • GlobeNewswire2 months ago

    Harrow Health to Announce First Quarter 2019 Financial Results on May 9, 2019

    Harrow Health, Inc. (HROW) today announced it will release first quarter 2019 financial results after the close of trading on Thursday, May 9, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 602-0380 for domestic callers or (862) 298-0970 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until June 9, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 48440.  The webcast replay will be available until August 9, 2019.

  • GlobeNewswire2 months ago

    ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meeting

    ImprimisRx, the ophthalmology-focused pharmaceutical compounding subsidiary of Harrow Health, Inc. (HROW), today announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the San Diego Convention Center in San Diego, CA May 3-7, 2019. With an estimated 11,000 attendees expected, this is the largest U.S. meeting of anterior segment surgeons, which integrates a scientific program dedicated to the needs of surgeons, specialists, practice management staff, and ophthalmic technicians and nurses.

  • Is Harrow Health's (NASDAQ:HROW) Share Price Gain Of 117% Well Earned?
    Simply Wall St.2 months ago

    Is Harrow Health's (NASDAQ:HROW) Share Price Gain Of 117% Well Earned?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It hasn't been the best quarter for Harrow Health, Inc. (NASDAQ:HROW) shareholders, since the...

  • Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry
    Simply Wall St.3 months ago

    Harrow Health, Inc. (NASDAQ:HROW) Delivered A Better ROE Than Its Industry

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return OnRead More...

  • Associated Press3 months ago

    Harrow: 4Q Earnings Snapshot

    SAN DIEGO (AP) _ Harrow Health, Inc. (HROW) on Tuesday reported fourth-quarter net income of $18.1 million, after reporting a loss in the same period a year earlier. On a per-share basis, the San Diego-based company said it had net income of 77 cents. The pharmaceutical and drug compounding company posted revenue of $11.4 million in the period.

  • GlobeNewswire3 months ago

    Harrow Health Announces Fourth Quarter 2018 Financial Results

    SAN DIEGO, March 12, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Fourth Quarter 2018 and Other Recent Notable Highlights:.

  • GlobeNewswire3 months ago

    Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019

    Harrow Health, Inc. (HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  Mark L. Baum, the company’s Chief Executive Officer, and Andrew R. Boll, its Chief Financial Officer, will be hosting one-on-one meetings at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting. Harrow Health, Inc. (HROW) owns a portfolio of healthcare businesses, including the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx.  The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health.  The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley.  Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first.  For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here.

  • GlobeNewswire4 months ago

    Harrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019

    Harrow Health, Inc. (HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019.  The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1:30 p.m. Pacific Daylight Time on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (844) 369-8770 for domestic callers or (862) 298-0840 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Harrow Health website by clicking here.  A dial in replay of the call will be available until April 12, 2019.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 44882.  The webcast replay will be available until June 12, 2019.

  • GlobeNewswire4 months ago

    Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulations

    Melt Pharmaceuticals, Inc., a specialty pharmaceutical company recently deconsolidated from Harrow Health, Inc. (HROW), today announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations.  U.S. Patents 10,166,240 and 10,179,136 relate to methods of use, formulation compositions and methods to manufacture the same, which the company intends to commercialize through its MELT-100 program and other planned drug development initiatives.  Both new patents have expiration dates in 2036. Melt Pharmaceuticals, Inc., is a development stage specialty pharmaceutical company focused on the development and commercialization of patented non-opioid and non-intravenous (or non-IV) sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings.  Melt intends to seek regulatory approval through the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway for these proprietary technologies.  Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States.

  • GlobeNewswire4 months ago

    Harrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property

    SAN DIEGO, Feb. 07, 2019 -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and.

  • GlobeNewswire4 months ago

    Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary

    Concurrent with the financing, Greg Madison has been hired as CEO of Melt Pharmaceuticals. Most recently, Mr. Madison was CEO of Keryx Biopharmaceuticals where he led the company’s transformation from development stage to a fully integrated 200+ employee commercial organization and drove impressive revenue growth by expanding the label for the company’s lead product.  Before Keryx, he was Chief Commercial Officer at specialty pharma company AMAG Pharmaceuticals and spent 12 years at Genzyme/Sanofi, ending as Vice-President and General Manager of the Renal division.

  • What Did Harrow Health, Inc.’s (NASDAQ:HROW) CEO Take Home Last Year?
    Simply Wall St.5 months ago

    What Did Harrow Health, Inc.’s (NASDAQ:HROW) CEO Take Home Last Year?

    In 2012 Mark Baum was appointed CEO of Harrow Health, Inc. (NASDAQ:HROW). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...